3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasm Metastasis
10
Lung Neoplasms
9
Carcinoma, Medullary
9
Neoplasms
6
Thyroid Neoplasms
5
Glioma
5
Glioblastoma
5
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Familial medullary thyroid carcinoma
2
Disease Progression
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Biliary Tract Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Interventions
Carboplatin
27
Paclitaxel
24
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Docetaxel
9
Pemetrexed
8
Everolimus
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
Nivolumab
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Irinotecan
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Gefitinib
4
Albumin-Bound Paclitaxel
4
vosaroxin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
vandetanib
×
Clear all
NCT00506051
2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1
Completed
21 enrolled